Newsbenzinga
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
· Published
Article summary
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
An excerpt from the original article.
Comments —
Loading comments…